Page 69 - 2021_10-Haematologica-web

Tr1 cells kill primary pediatric acute myeloid leukemia cells
Gibson B, et al. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel. Blood. 2012;120(16):3187-3205.
5. Yi T, Chen Y, Wang L, et al. Reciprocal dif- ferentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus- host disease. Blood. 2009;114(14):3101- 3112.
6. Wingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allo- geneic hematopoietic cell transplantation. J Clin Oncol. 2011;29(16):2230-2239.
7. Kumar S, Chen M, Gastineau D, et al. Effect of slow lymphocyte recovery and type of graft-versus-host disease prophylaxis on relapse after allogeneic bone marrow trans- plantation for acute myelogenous leukemia. Bone Marrow Transplant. 2001;28(10):951- 956.
8.Groux H, O’Garra A, Bigler M, et al. A CD4+T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997;389(6652):737-742.
9. Blazar BR, MacDonald KPA, Hill GR. Immune regulatory cell infusion for graft- versus-host disease prevention and therapy. Blood. 2018;131(24):2651-2660.
10. Roncarolo MG, Gregori S, Bacchetta R, Battaglia M, Gagliani N. The biology of T regulatory type 1 cells and their therapeutic application in immune-mediated diseases. Immunity. 2018;49(6):1004-1019.
11. Bacchetta R, Lucarelli B, Sartirana C, et al. Immunological outcome in haploidentical- HSC transplanted patients treated with IL- 10-anergized donor T cells. Front Immunol. 2014;5:16.
12. Serafini G, Andreani M, Testi M, et al. Type 1 regulatory T cells are associated with per- sistent split erythroid/lymphoid chimerism after allogeneic hematopoietic stem cell transplantation for thalassemia. Haematologica. 2009;94(10):1415-1426.
13. Locafaro G, Andolfi G, Russo F, et al. IL-10- engineered human CD4 + Tr1 cells elimi- nate myeloid leukemia in an HLA class I- dependent mechanism. Mol Ther. 2017; 25(10):2254-2269.
14.Andolfi G, Fousteri G, Rossetti M, et al. Enforced IL-10 expression confers type 1 regulatory T cell (Tr1) phenotype and func- tion to human CD4+ T cells. Mol Ther. 2012;20(9):1778-1790.
15. Zeller JC, Panoskaltsis-Mortari A, Murphy WJ, et al. Induction of CD4+ T cell alloanti- gen-specific hyporesponsiveness by IL-10 and TGF-beta. J Immunol. 1999;163(7):3684- 3691.
16. Zhang P, Lee JS, Gartlan KH, et al. Eomesodermin promotes the development of type 1 regulatory T (T R 1) cells. Sci Immunol. 2017;2(10):eaah7152.
17. Magnani CF, Alberigo G, Bacchetta R, et al. Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells. Eur J Immunol. 2011;41(6):1652-1662.
18. Guipouy D, Gertner-Dardenne J, Pfajfer L, German Y, Belmonte N, Dupré L. Granulysin- and granzyme-dependent elim-
ination of myeloid cells by therapeutic ova- specific type 1 regulatory T cells. Int Immunol. 2019;31(4):239-250.
131(5):748-754.
33. Krasinskas AM, Wasik MA, Kamoun M,
Schretzenmair R, Moore J, Salhany KE. The usefulness of CD64, other monocyte-associ- ated antigens, and CD45 gating in the sub- classification of acute myeloid leukemias with monocytic differentiation. Am J Clin Pathol. 1998;110(6):797-805.
34. Jenkins MR, Griffiths GM. The synapse and cytolytic machinery of cytotoxic T cells. Curr Opin Immunol. 2010;22(3):308-313.
35. Bausch-Fluck D, Goldmann U, Müller S, et al. The in silico human surfaceome. Proc Natl Acad Sci U S A. 2018;115(46):E10988- E10997.
36. Vaine CA, Soberman RJ. The CD200– CD200R1 inhibitory signaling pathway. In: Advances in Immunology. Elsevier; p191- 211.
37. Cherwinski HM, Murphy CA, Joyce BL, et al. The CD200 receptor is a novel and potent regulator of murine and human mast cell function. J Immunol. 2005;174(3):1348- 1356.
38. Coles SJ, Hills RK, Wang ECY, et al. Expression of CD200 on AML blasts directly suppresses memory T-cell function. Leukemia. 2012;26(9):2148-2151.
39. Betts MR, Brenchley JM, Price DA, et al. Sensitive and viable identification of anti- gen-specific CD8+ T cells by a flow cyto- metric assay for degranulation. J Immunol Methods. 2003;281(1-2):65-78.
40.Winer ES, Stone RM. Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches. Ther Adv Hematol. 2019;10:204062071986064.
41. Gorczyca W, Sun Z-Y, Cronin W, Li X, Mau S, Tugulea S. Immunophenotypic pattern of myeloid populations by flow cytometry analysis. In: Methods in Cell Biology. Elsevier; p221–266.
42. Raspadori D, Damiani D, Lenoci M, et al. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clini- cal prognosis. Leukemia. 2001;15(8):1161- 1164.
43. Elias S, Yamin R, Golomb L, et al. Immune evasion by oncogenic proteins of acute myeloid leukemia. Blood. 2014; 123(10): 1535-1543.
44. Balgobind BV, Zwaan CM, Pieters R, Van den Heuvel-Eibrink MM. The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia. Leukemia. 2011;25(8):1239-1248.
45. Schoch C, Schnittger S, Klaus M, Kern W, Hiddemann W, Haferlach T. AML with 11q23/MLL abnormalities as defined by the WHO classification: incidence, partner chro- mosomes, FAB subtype, age distribution, and prognostic impact in an unselected series of 1897 cytogenetically analyzed AML cases. Blood. 2003;102(7):2395-2402.
46.Jacobsohn DA, Loken MR, Fei M, et al. Outcomes of measurable residual disease in pediatric acute myeloid leukemia before and after hematopoietic stem cell trans- plant: validation of difference from normal flow cytometry with chimerism studies and Wilms tumor 1 gene expression. Biol Blood Marrow Transplant. 2018;24(10): 2040-2046.
19.Bolouri H, Farrar JE, Triche T, et al. The molecular landscape of pediatric acute myeloid leukemia reveals recurrent structur- al alterations and age-specific mutational interactions. Nat Med. 2017;24(1):103-112. Ho PA, Kutny MA, Alonzo TA, et al. Leukemic mutations in the methylation- associated genes DNMT3A and IDH2 are rare events in pediatric AML: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2011;57(2):204-209.
21.Radtke I, Mullighan CG, Ishii M, et al. Genomic analysis reveals few genetic alter- ations in pediatric acute myeloid leukemia. Proc Natl Acad Sci U S A. 2009; 106(31): 12944-12949.
22. Marceau-Renaut A, Duployez N, Ducourneau B, et al. Molecular profiling defines distinct prognostic subgroups in childhood AML: a report from the French ELAM02 Study Group. HemaSphere. 2018; 2(1):e31.
23. Juhl-Christensen C, Ommen HB, Aggerholm A, et al. Genetic and epigenetic similarities and differences between child- hood and adult AML: molecular profiling in childhood AML. Pediatr Blood Cancer. 2012;58(4):525-531.
24. Tonks A, Hills R, White P, et al. CD200 as a prognostic factor in acute myeloid leukaemia. Leukemia. 2007;21(3):566-568.
25. Tiribelli M, Geromin A, Cavallin M, et al. ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML. Eur J Haematol. 2017;99(3):269-274.
26. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15(12):550.
27.Gu Z, Eils R, Schlesner M. Complex heatmaps reveal patterns and correlations in multidimensional genomic data. Bioinformatics. 2016;32(18):2847-2849.
28.Merico D, Isserlin R, Stueker O, Emili A, Bader GD. Enrichment map: a network- based method for gene-set enrichment visu- alization and interpretation. PLoS One. 2010;5(11):e13984.
29. Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neo- plasms and acute leukemia. Blood. 2016;127(20):2391-2405.
30. Mootha VK, Lindgren CM, Eriksson K-F, et al. PGC-1α-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267-273.
31. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowl- edge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545-15550.
32. Dunphy CH, Tang W. The value of CD64 expression in distinguishing acute myeloid leukemia with monocytic differentiation from other subtypes of acute myeloid leukemia: a flow cytometric analysis of 64 cases. Arch Pathol Lab Med. 2007;
20.
haematologica | 2021; 106(10)
2597